Levels of Mycoplasma genitalium Antimicrobial Resistance Differ by Both Region and Gender in the State of Queensland, Australia: Implications for Treatment Guidelines

E. L. Sweeney, E. Trembizki, C. Bletchly, C. S. Bradshaw, A. Menon, F. Francis, J. Langton-Lockton, G. R. Nimmo, D. M. Whiley

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)

Abstract

Mycoplasma genitalium is frequently associated with urogenital and rectal infections, with the number of cases of macrolide-resistant and quinolone-resistant M. genitalium infection continuing to increase. In this study, we examined the levels of resistance to these two common antibiotic treatments in geographically distinct locations in Queensland, Australia. Samples were screened for macrolide resistance-associated mutations using a commercially available kit (ResistancePlus MG; SpeeDx), and quinolone resistance-associated mutations were identified by PCR and DNA sequencing. Comparisons between antibiotic resistance mutations and location/gender were performed. The levels of M. genitalium macrolide resistance were high across both locations (62%). Quinolone resistance mutations were found in ∼10% of all samples, with a number of samples harboring mutations conferring resistance to both macrolides and quinolones. Quinolone resistance was higher in southeast Queensland than in north Queensland, and this was consistent in both males and females (P = 0.007). The M. genitalium isolates in rectal swab samples from males harbored high levels of macrolide (75.9%) and quinolone (19%) resistance, with 15.5% harboring resistance to both classes of antibiotics. Overall, the lowest observed level of resistance was to quinolones in females from north Queensland (1.6%). These data highlight the high levels of antibiotic resistance in M. genitalium isolates within Queensland and the challenges faced by sexually transmitted infection clinicians in managing these infections. The data do, however, show that the levels of antibiotic resistance may differ between populations within the same state, which has implications for clinical management and treatment guidelines. These findings also support the need for ongoing antibiotic resistance surveillance and tailored treatment.

Original languageEnglish
Article numbere01555-18
Number of pages10
JournalJournal of Clinical Microbiology
Volume57
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

Keywords

  • antimicrobial resistance
  • Australia
  • azithromycin
  • macrolide
  • moxifloxacin
  • Mycoplasma genitalium
  • Queensland
  • quinolone
  • sexually transmitted infection

Cite this